Iovance Biotherapeutics, Inc. (IOVA)
| Market Cap | 875.31M |
| Revenue (ttm) | 250.43M |
| Net Income (ttm) | -397.63M |
| Shares Out | 396.97M |
| EPS (ttm) | -1.20 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,472,755 |
| Open | 2.140 |
| Previous Close | 2.135 |
| Day's Range | 2.140 - 2.220 |
| 52-Week Range | 1.639 - 9.300 |
| Beta | 0.83 |
| Analysts | Buy |
| Price Target | 10.36 (+369.84%) |
| Earnings Date | Nov 6, 2025 |
About IOVA
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It develops... [Read more]
Financial Performance
In 2024, Iovance Biotherapeutics's revenue was $164.07 million, an increase of 13698.99% compared to the previous year's $1.19 million. Losses were -$372.18 million, -16.18% less than in 2023.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for IOVA stock is "Buy." The 12-month stock price target is $10.36, which is an increase of 369.84% from the latest price.
News
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and deliveri...
Iovance Biotherapeutics: Base-Case Q3 Report Keeps 'Show Me' Mode
Iovance Biotherapeutics remains a Sell due to ongoing dilution risk, sub-consensus revenue, and only modest margin improvements. Q3 revenue landed in the base case at $68 million, missing estimates, w...
Down 75% in 12 Months, Can Iovance Biotherapeutics Stock Turn Things Around?
Iovance obtained approval for Amtagvi last year, which has given its top line a big boost. This year, the company anticipates it can generate up to $300 million in sales.
2 Small-Cap Stocks With Far More Upside Than Any "Magnificent Seven" Stock, According to Wall Street
Iovance Biotherapeutics and Intellia Therapeutics are two innovative small-cap biotechs. Both companies face serious issues despite Wall Street's high price targets for them.
Iovance Biotherapeutics, Inc. (IOVA) Q3 2025 Earnings Call Transcript
Iovance Biotherapeutics, Inc. ( IOVA) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Sara Pellegrino - Senior Vice President of Investor Relations & Corporate Communications ...
IOVANCE INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Continues Investigation on Behalf of Long-Term Iovance, Inc. Stockholders
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Iovance (IOVA) To Contact Him Directly To Discuss Their Options If you are a long-term stoc...
Better Beaten-Down Stock: Iovance Biotherapeutics vs. Teladoc Health
Here's a great way to earn strong market returns over the long term: Identify companies that have been ignored or underestimated by most investors but have attractive prospects; buy their shares at a ...
Is Iovance Biotherapeutics Stock Your Ticket to Becoming a Millionaire?
Most investors don't truly expect a single, relatively small trade to explode into a seven-figure holding. On the other hand, the prospect can't be entirely ruled out either.
Iovance: Q3 Earnings May Smart, But Long Term Bull Thesis Remains In Play
Iovance Biotherapeutics (IOVA) maintains a Buy rating, supported by growing Amtagvi sales, promising efficacy data, and ongoing label expansion opportunities. IOVA's restructuring aims to cut over $10...
Can This Beaten-Down Stock Bounce Back?
Last year, Iovance Biotherapeutics (IOVA -1.59%), a small-cap biotech, made a major breakthrough. The company earned approval for Amtagvi, which became the first medicine of its kind to receive regula...
Iovance Biotherapeutics to Present at Upcoming Conferences
SAN CARLOS, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor inf...
If You'd Invested $1,000 in IOVA 3 Years Ago, Here's How Much You'd Have Today
For a roller-coaster stock, look no further than Iovance Biotherapeutics (IOVA -1.22%).
Why Iovance Biotherapeutics Stock Got Mashed on Monday
Monday won't go down as a particularly memorable trading session on the stock market. It also won't be marked as a great day for shareholders of biotech Iovance Biotherapeutics (IOVA -5.95%).
1 Beaten-Down Stock That Could Soar By 261%, According to Wall Street
There's at least one good thing to say about Iovance Biotherapeutics (IOVA 5.71%), a small-cap biotech. The drugmaker is an innovative company.
Iovance Biotherapeutics: Tough Decisions Being Made But Catalysts In H2'25
IOVA's Amtagvi (lifileucel) launch shows progress with Q2'25 revenue growth, helping rebuild confidence after prior stagnation. Cash burn remains a concern, but the company announced a restructuring w...
Why Iovance Biotherapeutics Stock Was Climbing Today
A piece of good news on the regulatory front and a subsequent bullish analyst update were the factors driving Iovance Biotherapeutics (IOVA 5.00%) stock higher on Tuesday. The shares were almost 6% in...
Iovance's Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma
First T cell therapy for a solid tumor cancer and first treatment option approved in Canada for advanced melanoma after anti-PD-1 and targeted therapy
Why Iovance Biotherapeutics Stock Plummeted Today
Investors are typically quite harsh on publicly traded companies that don't make their quarterly estimates, a dynamic vividly on display Friday with biotech stock Iovance Biotherapeutics (IOVA -20.08%...
Iovance Biotherapeutics, Inc. (IOVA) Q2 2025 Earnings Call Transcript
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Daniel G. Kirby - Chief Commercial Officer Frederick G.
Iovance (IOVA) Q2 Revenue Jumps 93%
Iovance (IOVA) Q2 Revenue Jumps 93%
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025
$60.0M in 2Q25 Total Product Revenue More than 100 Patients Treated with Amtagvi® in 2Q25 Strategic Restructuring Extends Cash Runway into 4Q26 FY25 Total Product Revenue Guidance of $250M-$300M Reite...
Is Iovance Biotherapeutics Stock Due for a Big Rally?
Shares of Iovance Biotherapeutics (IOVA -1.02%) have been in a free fall this past year, but in recent weeks, they have experienced a bit of a surge in value. The volatile biotech stock has been picki...
This Beaten-Down Healthcare Stock Could Jump 720%, According to a Wall Street Analyst. Is It Time to Buy?
Shares of Iovance Biotherapeutics (IOVA -5.91%) are down about 75% from a high-water mark they set last December. Up and down Wall Street, investment bank analysts tasked with following the commercial...
Here's why Iova stock surged 32% today and why the rally might not be over
Iova stock rallied 32% on Wednesday, snapping out of a long, sluggish stretch that had frustrated investors for months. The Iovance Biotherapeutics (NASDAQ: IOVA) shares have been stuck in a tight ran...
This Healthcare Stock Just Hit a 52-Week Low -- but Wall Street Sees 380% Upside
Investing in penny stocks -- companies with share prices under around $5 apiece -- could lead to monster returns over the long run. The flip side is that these corporations tend to carry above-average...